期刊文献+

重组痘苗病毒对不同哺乳动物细胞株的感染效率及EGFP表达水平研究 被引量:2

The Infection Efficiencies and EGFP Expression Levels of Recombinant Vaccinia Virus in Different Mammalian Cell Lines
下载PDF
导出
摘要 研究重组痘苗病毒对不同哺乳动物细胞的感染效率及表达水平,可为痘苗病毒表达系统宿主细胞的正确选择提供依据.本研究利用重组绿色荧光蛋白基因的痘苗病毒WR-EGFP同时感染不同的哺乳动物细胞株,利用流式细胞仪检测EGFP的表达强度.共使用20种哺乳动物细胞株,其中10种人类组织细胞,2种猴组织细胞,8种小鼠组织细胞.结果表明,重组痘苗病毒WR-EGFP对鼠细胞系BHK21和人细胞系A-549的感染效率和表达效率最佳;整体看,痘苗病毒对多数灵长类动物细胞的感染效率和表达效率优于鼠细胞;对贴壁细胞的感染效率和表达效率明显优于悬浮细胞;但没有特别的组织偏嗜性. Vaccinia virus was widely used as gene expressing vector in mammalian cell lines and candidate recombinant vaccine vector,thus parallel comparation of the infection and expression efficiencies of recombinant vaccinia virus in different mammalian cell lines is essential for correctly choicing suitable expressing host cell lines. In this study, different MOI of recombinant vaccinia virus WR-EGFP were used to infect several different mammalian cell lines simultaneously,after 48 h p. o. i. ,and flow cytometer was used to detect the intensity of green fluorescence emitted by GFP. Twenty cell lines, 2 monkey cell lines and 8 rodent cell lines. Results showed kidney cell BHK21 and human cell A-549 with the highest infection different mammalian cell lines were infected, including 10 human that recombinant vaccinia virus WR-EGFP could infect hamster efficiency and expression efficiency. For most primate cell lines, WR-EGFP has higher infection efficiency and expression efficiency than rodent cell lines,and both efficiencies are higher in adherent culture cell lines than in suspend culture cell lines,but no obvious partiality was observed for cells coming from different organ origin. At 24 h p. o. i. ,different MOI of WR-EGFP infected cell and expressed GFP with markedly different intensity,but at 48 h p. o. i., the difference became negligible,which implies lower dosage of virus and longer culture can be used to express target proteins. Comparing with baculoviruses, vaccinia virus has higher infection and expression efficiency in mammalian cell lines with lower MOI,but may lysis most cell lines after 72 h p. o. i. , which seldom happen when infecting with baculoviruses.
出处 《厦门大学学报(自然科学版)》 CAS CSCD 北大核心 2005年第6期866-869,共4页 Journal of Xiamen University:Natural Science
基金 福建省科技重大专项(2004YZ01)资助
关键词 重组痘苗病毒 绿色荧光蛋白 流式细胞仪 vaccinia virus green fluorescent protein flow cytometer
  • 相关文献

参考文献9

  • 1[1]Carroll M W, Moss B. Poxviruses as expression vectors [J]. Current Opinion Biotech. , 1997,8 (5):573- 577.
  • 2[2]Kaufman H L,Wang W,Manola J,et al. Phase Ⅱ randomized study of vaccine treatment of advanced prostate cancer (E7897):a trial of the Eastern Cooperative Oncology Group[J]. J. Clin. Oncol. ,2004,22(11) :2 122-2 132.
  • 3[3]Roque-Resendiz J L, Rosales R, Herion P. MVA ROP2 vaccinia virus recombinant as a vaccine candidate for toxoplasmosis[J]. Parasitology, 2004,128 (Pt 4 ):397- 405.
  • 4[4]Corona Gutierrez C M,Tinoco A,Navarro T,et al. Therapeutic vaccination with MVA E2 can eliminate precancerous lesions (CIN 1 ,CIN 2,and CIN 3) associated with infection by oncogenic human papillomavirus [J]. Hum.Gene Ther. ,2004,15(5):421-431.
  • 5[5]Bleckwenn N A,Bentley W E,Shiloach J,et al. Exploring vaccinia virus as a toolfor large-scale recombinant protein expression[J]. Biotechnol. Prog. , 2003,19(1): 130- 136.
  • 6[7]Kost T A, Condreay J P. Recombinant baculoviruses as mammalian cell gene-delivery vectors[J]. Trends Biotechnol. ,2002,20(4): 173-180.
  • 7[8]Huser A,Hofmann C. Baculovirus vectors:novel mammalian cell gene-delivery vehicles and their applications[J].Am.J.Pharmacogenomics,2003,3:53-63.
  • 8程通,许辰煜,王颖彬,陈敏,吴婷,谢小燕,张军,夏宁邵.杆状病毒用于哺乳动物细胞快速高效表达外源基因的研究[J].生物工程学报,2003,19(5):581-586. 被引量:5
  • 9许辰煜,程通,卢五迅,陈敏,吴婷,王颖彬,张军,夏宁邵.杆状病毒对不同哺乳动物细胞基因转移及表达效率的研究[J].生物工程学报,2004,20(1):73-77. 被引量:8

二级参考文献10

  • 1Carbonell L F, Miller L K. Baculovims interaction with nontarset organisms:a vs-borne reposter gene is not expressed in two mammalian cell lines. Appl Environ Micro Biol, 1987,53:1412- 1417.
  • 2Hofmann C, Sandig V, Strauss M et al. Efficient gene transfer into human hepatocytes by baculovirus vectors. Proc Natl Acad Sci USA,1995,92:10099 - 10103.
  • 3Boyce F M, Bucher N L R. Baculovirus mediated gene transfer into mammalian cells. Proc Natl Acad Sci USA, 1996 , 93 : 2348 - 2352.
  • 4Condreay J P, Witherspoon S M, Clay W C et al. Transient and stable gene expression in mammalian cells transduced with a recombinant baculovirus vector, Proc Natl Acad Sci USA, 1999,96( 1 ) : 127 - 132.
  • 5Duisit G, Saleun S, Douthe S et al. Baculovirus vector require selectrostatic interactions including heparan sulfate for efficient gene transfer in mammalian cells. J Gene Med, 1999,1(2):93 - 102.
  • 6Delaney W E, lsom H C. Hepatitis B virus replication in human HepG2 cells mediated by hepatitis B virus recombinant baculovirus.Hepatology, 1998,28 : 1134 - 1146.
  • 7Bae-to-Bae baculovirus expression systems instruction manual. Invitrogen life technologies,2002.
  • 8Shoji I, Aizaki H, Tani H et al. Efficient gene transfer into various mammalian cells, including non-hepatic cells, by baculovirus vectors.J Gen Virol, 1997,78:2657 - 2664.
  • 9Kost T A, Condreay J P. Recombinant baculoviruses as mammalian cell gene-delivery vectors.Trends biotechnol,2002,20(4):173-180
  • 10程通,许辰煜,王颖彬,陈敏,吴婷,谢小燕,张军,夏宁邵.杆状病毒用于哺乳动物细胞快速高效表达外源基因的研究[J].生物工程学报,2003,19(5):581-586. 被引量:5

共引文献10

同被引文献16

  • 1沈荣显 徐振东 等.马传染性贫血免疫的研究[J].中国农业科学,1979,(4):1-15.
  • 2Newman MJ. Heterologous prime-boost vaccination strategies for HIV-1:augmenting cellular immune responses[J]. Curr Opin Investig Drugs,2002,3(3) :374-378.
  • 3Qing Fang, Lin Yang, Weijun Zhu, et al. Host range, growth property, and virulence of the smallpox vaccine:Vaccinia virus Tian Tan strain[J]. Virology , 2005,335:242-251.
  • 4Naldini L,Blomer U,Gallay P ,et al. In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector[J]. Science, 1996,272(5259) : 263 - 267.
  • 5Iwakuma T, Cui Y, Chang L J. Self-inactivating lentiviral vectors with U3 and U5 modifications[J]. Virology, 1999,261(1):120- 132.
  • 6Klages N, Zufferey R, Trono D. A stable system for the high-titer production of multiply attenuated lentiviral vectors[J]. Mol Ther, 2000,2(2) : 170- 176.
  • 7Anson D S. The use of retroviral vectors for gene therapy-what are the risks? A review of retroviral pathogenesis and its relevance to retroviral vector-mediated gene delivery[J]. Genet Vaccines Ther, 2004,2 (9) : 1 - 13.
  • 8Lai Z,Brady R O. Gene transfer into the central nervous system in vivo using a recombinanat lentivirus vector[J]. J Neurosci Res, 2002,67 (3) : 363- 371.
  • 9Ralph G S, Binley K, Wong L F, et al. Gene therapy for neurodegenerative and ocular diseases using lentiviral vectors[J]. Clin Sci (Lond), 2006,110 ( 1 ): 37 - 46.
  • 10Philpott N J,Thrasher A J. Use of nonintegrating lentiviral vectors for gene therapy[J]. Hum Gene Ther,2007,18 (6):483-489.

引证文献2

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部